Based in Vancouver, Canada, Neuromed Pharmaceuticals focuses on the research, production, and marketing of pain management drugs. Their innovative approach targets neuronal calcium channels to treat neurological disorders, with a primary focus on chronic pain, anxiety, and stroke. By developing therapies that aid in the recovery from chronic pain, Neuromed Pharmaceuticals aims to improve the lives of patients suffering from these conditions. The company was founded in 1998 and was acquired by Zalicus in December 2009, solidifying its presence in the Canadian and US markets.